Debate Intensifies Over Focal Therapy as New Data Shows Promising Survival

Focal therapy aims to ablate specific prostate lesions using technologies such as cryotherapy, laser ablation or high-intensity focused ultrasound, often in a single outpatient session. Advocates cite a UK cohort where just 0.1% of treated men died of prostate cancer after ten years, with fewer side effects and higher satisfaction than traditional surgery or radiation. The American Urological Association, however, maintains that the method remains experimental and should be confined to studies or registries.

Skeptics argue that robust head-to-head trials are lacking and that many recipients fall outside the intermediate-risk group the guidelines target. Proponents note the procedure’s short duration, minimal recovery time and the possibility of repeat treatments if cancer recurs, while opponents warn of potential overtreatment and uncertain long-term survival compared with radical options.